Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) is 19.78% higher on its value in year-to-date trading and has touched a low of $0.56 and a high of $3.83 in the current 52-week trading range. The SLRX stock was last observed hovering at around $1.09 in the last trading session, with the day’s gains setting it 0.1% off its average median price target of $4.40 for the next 12 months. It is also 76.2% off the consensus price target high of $5.00 offered by 2 analysts, but current levels are 68.68% higher than the price target low of $3.80 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $1.19, the stock is 26.56% and 43.39% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.84 million and changing 9.18% at the moment leaves the stock 22.18% off its SMA200. SLRX registered -70.46% loss for a year compared to 6-month loss of -26.35%. The firm has a 50-day simple moving average (SMA 50) of $0.8980 and a 200-day simple moving average (SMA200) of $0.9787.
The stock witnessed a -9.92% gain in the last 1 month and extending the period to 3 months gives it a 34.73%, and is 22.20% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 13.88% over the week and 11.31% over the month.
Salarius Pharmaceuticals Inc. (SLRX) has around 7 employees, a market worth around $21.20M and $4.80M in sales. Distance from 52-week low is 114.36% and -68.93% from its 52-week high. The company has generated returns on investments over the last 12 months (-74.50%).
Salarius Pharmaceuticals Inc. (SLRX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Salarius Pharmaceuticals Inc. (SLRX) is a “Buy”. 2 analysts offering their recommendations for the stock have an average rating of 1.50, where 0 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Salarius Pharmaceuticals Inc. is expected to release its quarterly report on 05/20/2021 and quarterly earnings per share for the current quarter are estimated at -$0.11 with sales reaching $1.48M over the same period.The EPS is expected to grow by 93.00% this year, but quarterly earnings will post 51.50% year-over-year. Quarterly sales are estimated to grow 42.40% in year-over-year returns.
Salarius Pharmaceuticals Inc. (SLRX) Top Institutional Holders
24 institutions hold shares in Salarius Pharmaceuticals Inc. (SLRX), with 1.04M shares held by insiders accounting for 5.23% while institutional investors hold 27.70% of the company’s shares. The shares outstanding are 17.97M, and float is at 16.26M with Short Float at 2.87%. Institutions hold 26.25% of the Float.
The top institutional shareholder in the company is Worth Venture Partners, LLC with over 0.26 million shares valued at $0.22 million. The investor’s holdings represent 1.30% of the SLRX Shares outstanding. As of Sep 29, 2020, the second largest holder is Kepos Capital Lp with 0.13 million shares valued at $0.11 million to account for 0.63% of the shares outstanding. The other top investors are Douglass Winthrop Advisors LLC which holds 78806.0 shares representing 0.40% and valued at over $66504.0, while Tower Research Capital LLC (TRC) holds 0.27% of the shares totaling 52619.0 with a market value of $44405.0.
Salarius Pharmaceuticals Inc. (SLRX) Insider Activity
A total of 6 insider transactions have happened at Salarius Pharmaceuticals Inc. (SLRX) in the last six months, with sales accounting for 0 and purchases happening 6 times. The most recent transaction is an insider purchase by HANISH ARNOLD C, the company’s Director. SEC filings show that HANISH ARNOLD C bought 4,000 shares of the company’s common stock on Aug 21 at a price of $0.98 per share for a total of $3920.0. Following the purchase, the insider now owns 11350.0 shares.
Salarius Pharmaceuticals Inc. disclosed in a document filed with the SEC on Aug 19 that Arthur David J. (Chief Executive Officer) bought a total of 2,000 shares of the company’s common stock. The trade occurred on Aug 19 and was made at $1.01 per share for $2020.0. Following the transaction, the insider now directly holds 2000.0 shares of the SLRX stock.
Still, SEC filings show that on Aug 17, Rosenblum Mark J (Exec VP Finance, CFO) acquired 5,000 shares at an average price of $1.00 for $5000.0. The insider now directly holds 12,000 shares of Salarius Pharmaceuticals Inc. (SLRX).